ASN
KROS icon

Advisory Services Network’s Keros Therapeutics KROS Stock Holding History

Advisory Services Network’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-123
Closed -$1.36K – 3526
2026
Q1 		$1.36K Buy
+123
New +$1.9K ﹤0.01% 4243
2025
Q4 		– Sell
-30
Closed -$475 – 3173
2025
Q3 		$475 Buy
+30
New +$443 ﹤0.01% 4062

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Advisory Services Network's KROS Position: Q2 2026 in Review

Advisory Services Network sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 123 shares — an estimated $1.36K sold.

Advisory Services Network first reported a position in KROS in Q3 2025 and held it in 2 quarters. The position peaked at $1.36K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Advisory Services Network reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advisory Services Network sold 123 Keros Therapeutics shares in Q2 2026, an estimated $1.36K.
  • Advisory Services Network first reported a position in Keros Therapeutics in Q3 2025 and held it in 2 quarters.
  • Advisory Services Network's Keros Therapeutics position peaked at $1.36K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.